Argenx Se (ARGX) Gross Profit (2022 - 2026)
Argenx Se (ARGX) posted Gross Profit of $1.2 billion for Q1 2026, up 3.61% on a QoQ basis from $1.1 billion in Q4 2025, and up 66.01% year-over-year from $709.0 million in Q1 2025.
Argenx Se (ARGX) Gross Profit (2022 - 2026) Analysis & Trends
Argenx Se's Gross Profit history runs 5 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- Quarterly Gross Profit rose 66.01% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 billion (up 80.26% YoY) and the FY2025 annual result came in at $3.7 billion, up 88.94% from the prior year.
- Gross Profit was $1.2 billion for Q1 2026 at Argenx Se, up from $1.1 billion in the prior quarter.
- Across five years, Gross Profit topped out at $1.2 billion in Q1 2026 and bottomed at $19.8 million in Q1 2022.
- A 5-year average of $487.1 million and a median of $355.1 million in 2024 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2023 — Gross Profit jumped 908.98% — and 2026, when it jumped 66.01%.
- Argenx Se's Gross Profit stood at $160.6 million in 2022, then soared by 108.5% to $334.9 million in 2023, then surged by 98.38% to $664.3 million in 2024, then jumped by 71.01% to $1.1 billion in 2025, then rose by 3.61% to $1.2 billion in 2026.
- Business Quant data shows ARGX's Gross Profit at $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.18 Bn |
| Mar 31, 2026 | 1.18 Bn |
| Dec 31, 2025 | 1.14 Bn |
| Dec 31, 2025 | 1.14 Bn |
| Sep 30, 2025 | 1.02 Bn |
| Sep 30, 2025 | 1.02 Bn |
| Jun 30, 2025 | 837.85 Mn |
| Jun 30, 2025 | 837.85 Mn |
| Mar 31, 2025 | 709.00 Mn |
| Mar 31, 2025 | 709.00 Mn |
| Dec 31, 2024 | 664.31 Mn |
| Dec 31, 2024 | 664.31 Mn |
| Sep 30, 2024 | 513.93 Mn |
| Sep 30, 2024 | 513.93 Mn |
| Jun 30, 2024 | 425.25 Mn |
| Jun 30, 2024 | 425.25 Mn |
| Mar 31, 2024 | 355.11 Mn |
| Mar 31, 2024 | 355.11 Mn |
| Dec 31, 2023 | 334.87 Mn |
| Dec 31, 2023 | 334.87 Mn |